Medable is on a mission to reduce clinical trial timelines by 50 percent. The company’s global decentralized trial platform streamlines design, recruitment, retention and data quality, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. As the world has seen with recent events, traditional trial processes and timelines are insufficient to meet the global need for clinical research.
Limiting trials to a handful or two of physical sites inherently limits patient access. Restricting interaction to in-person visits is not only grossly inefficient, but it also limits data frequency and quality. And during a crisis like the COVID-19 pandemic, it’s simply infeasible. Decentralized trials (also known as virtual trials) “untether” trials from physical sites, improving patient access to new therapies while accelerating trial timelines.
There are currently more than 55,000 interventional clinical trials underway worldwide, actively enrolling and providing care for participants. Of the 55,000 trials in flight, some are good candidates for a fully decentralized model—while many others can be managed in a hybrid model. Patients can be recruited and consented remotely.
Physician “visits” can be conducted remotely via telemedicine. Data can be captured remotely (and frequently) via medical devices and mobile technology. Over the past several years, Medable has built a unified, modular digital platform that works as a service to streamline clinical trials with direct-to-patient technologies. The platform connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes.
The platform is used by leading biopharma sponsors and clinical research organizations worldwide, and has been used for trials in 30+ countries and 26 languages. The paradigm is shifting – quickly. Decentralized trials are no longer a nice-to-have. Reducing trial timelines has to be a long-term industry imperative, whether it’s streamlining trials for critical vaccines, reducing timelines for other therapies, or initiating new trials to address the 7,000+ rare diseases that have no therapies on the market. Now is the time for decentralized trials, so we can get effective therapies to more patients faster.
Medable is the leading global platform for decentralized trials. Its software accelerates clinical drug development, enabling effective new therapies to reach patients faster.
Statistics:
Year Founded: 2012
Founded By:
Dr. Michelle Longmire, CEO Tim Smith, CTO
Perry Robinson, General Counsel, Chief Compliance Officer
